Abstract
Although the sedative and extrapyramidal side effects associated with first-generation antipsychotics are well known, some second-generation antipsychotics are also associated with substantial sedation and activation effects. In this Academic Highlights article, 4 experts on depression from the fields of psychiatry and primary care take a closer look at activation and sedation effects of atypical antipsychotics in patients with MDD. They examine the likelihood of each agent to cause these effects; the impact of these effects on patient functioning, quality of life, and treatment adherence; and the question of whether leveraging activation and sedation to address acute symptoms is ever advisable.
© Copyright 2019 Physicians Postgraduate Press, Inc.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antidepressive Agents / adverse effects*
-
Antidepressive Agents / therapeutic use*
-
Antipsychotic Agents / adverse effects*
-
Antipsychotic Agents / therapeutic use*
-
Anxiety Disorders / drug therapy
-
Anxiety Disorders / psychology
-
Aripiprazole / adverse effects
-
Aripiprazole / therapeutic use
-
Arousal / drug effects*
-
Comorbidity
-
Delayed-Action Preparations
-
Depressive Disorder, Major / drug therapy*
-
Depressive Disorder, Major / psychology
-
Drug Approval
-
Drug Therapy, Combination
-
Female
-
Humans
-
Hypnotics and Sedatives*
-
Male
-
Middle Aged
-
Practice Patterns, Physicians'
-
Quality of Life / psychology
-
Quetiapine Fumarate / adverse effects
-
Quetiapine Fumarate / therapeutic use
-
Quinolones / adverse effects
-
Quinolones / therapeutic use
-
Sleep Initiation and Maintenance Disorders / drug therapy
-
Sleep Initiation and Maintenance Disorders / psychology
-
Thiophenes / adverse effects
-
Thiophenes / therapeutic use
Substances
-
Antidepressive Agents
-
Antipsychotic Agents
-
Delayed-Action Preparations
-
Hypnotics and Sedatives
-
Quinolones
-
Thiophenes
-
brexpiprazole
-
Quetiapine Fumarate
-
Aripiprazole